PetVivo
Holdings, Inc. (Nasdaq: PETV), an emerging
biomedical device company focused on the commercialization of
innovative medical therapeutics for animals, announces financial
results for its fiscal year ended March 31, 2023 (“fiscal 2023”).
Key highlights for our fiscal year ended March
31, 2023, were:
|
● |
Revenues increased to $917,162 in fiscal 2023, compared to revenues
of $115,586 for our fiscal year ended March 31, 2022 (“fiscal
2022”); |
|
|
|
|
● |
Entered into an exclusive distribution agreement (“Distribution
Agreement”) with MWI Veterinary Supply, a leading distributor of
animal health products and a subsidiary of AmerisourceBergen
(“MWI”) in June 2022. We recognized revenues from product sales
under the Distribution Agreement of $636,345 or 69% of total
revenues for the year ended March 31, 2023; |
|
|
|
|
● |
Increased brand awareness and market awareness by participating in
several key national trade shows and conferences, including having
Dr. Joseph Manning, DVM, the Company’s Senior Technical
Veterinarian present on the use of Spryng™ at the American
Association of Equine Practitioners Annual Conference in November
2022; |
|
|
|
|
● |
Reported results on the first cohort of dogs in a clinical study,
which examined the benefit and tolerability of an intra-articular
injection of Spryng™ into the stifle joint of dogs with suspected
cruciate ligament damage or tear (similar to an anterior cruciate
ligament (“ACL”) tear in humans) in March 2023. The preliminary
results demonstrated that Spryng™ may be a viable alternative for
medical management of dogs with an ACL injury; and |
|
|
|
|
● |
Signed a lease agreement for a new production and warehouse space
in Edina, Minnesota in January 2023. We plan to have this facility
operational in the fourth quarter of our fiscal year ending March
31, 2024 (“fiscal 2024”). |
Management
Commentary
John Lai, CEO, commented, “I am pleased by our
team’s performance. We executed well on our strategy of developing
clinical data on the efficacy of Spryng™, increased distribution
through MWI, increased market awareness of Spryng™ to veterinarians
and delivered strong revenue growth in fiscal 2023.
We are excited about the preliminary clinical
results from the cruciate ligament study on canines and expect to
receive the final clinical results in Q2 of fiscal 2024. We expect
to use this clinical data to expand the application of Spryng™ to
treat canines and felines who have cruciate ligament injuries.
We are also taking several steps to position the
Company for future success in fiscal 2024. We plan to add more
sales and marketing personnel to support our distribution
relationship with MWI and veterinary clinics, add to our technical
service teams, complete clinical studies in equine, canine and
feline companion animals, increase adoption of Spryng™ by key
opinion leaders and increase marketing awareness through trade
shows and digital outreach.”
For The Fiscal
Year Ended March 31,
2023 Compared to
The Fiscal Year
Ended March 31,
2022
Total Revenues. Revenues were
$917,162 in fiscal 2023 compared to $115,586 for fiscal 2022.
Revenues in fiscal 2023 consisted of sales of our Spryng™ products
to MWI of $636,345 and to veterinary clinics in the amount of
$280,817. In fiscal 2022, our revenues of $115,586 consisted of
sales to veterinary clinics. The increase in our revenues in fiscal
2023 is due to sales to MWI pursuant to our Distribution Agreement
and increased sales to veterinary clinics.
Total Cost of Sales. Cost of
sales was $526,817 in fiscal 2023 compared to $201,154 for fiscal
2022. Cost of sales includes product costs related to the sale of
our Spryng™ products and labor and overhead costs. The increase in
cost of sales in fiscal 2023 is due to the increased sales to MWI
pursuant to our Distribution Agreement and increased sales to
veterinary clinics.
Operating Expenses. Operating
expenses increased to $9,123,797 in fiscal 2023 compared to
$4,970,960 in fiscal 2022. Operating expenses consisted of general
and administrative (“G&A”), sales and marketing, and research
and development expenses. The increase is primarily due to
increased G&A expenses and sales and marketing expenses related
to the sale of our Spryng™ products.
General and administrative expenses were
$5,022,943 and $3,148,494 in fiscal 2023 and 2022, respectively.
General and administrative expenses include compensation and
benefits, contracted services, consulting fees, stock compensation,
and incremental public company costs.
Sales and marketing expenses were $3,410,277 and
$1,347,585 in fiscal 2023 and 2022, respectively. Sales and
marketing expenses include compensation, consulting, tradeshows,
and stock compensation costs to support the launch of our Spryng™
products.
Research and development (“R&D”) expenses
were $690,577 and $474,881 in fiscal 2023 and 2022, respectively.
The increase was related to clinical studies and efforts to support
the launch of Spryng™.
Operating Loss. As a result of
the foregoing, our operating loss was $8,733,452 and $5,056,528 in
fiscal 2023 and 2022, respectively. The increase was related to the
costs to support the launch of Spryng™ and the incremental public
company costs.
Other
Income. Other income was
$15,844 in fiscal 2023 as compared to $41,533 in fiscal 2022. Other
income in fiscal 2023 consisted of net interest income of $15,844.
Other income in fiscal 2022 consisted of the forgiveness of PPP
Loan of $31,680 and net interest income of $9,853.
Net Loss. Our net loss in
fiscal 2023 was $8,717,608 or ($0.85 per share) as compared to a
net loss of $5,014,995 or ($0.57) per share in fiscal 2022. The
weighted average number of shares outstanding was 10,222,994
compared to 8,760,877 for fiscal 2023 and 2022, respectively.
Balance Sheet
and Inventory
As of March 31, 2023, our current assets were
$1,423,980 including $475,314 in cash and cash equivalents. In
comparison, our current liabilities as of that date were $1,453,680
including $1,368,595 of accounts payable and accrued expenses. Our
working capital deficit as of March 31, 2023 was $29,700.
At March 31, 2023, the Company’s inventory had a
carrying value of $370,283.
Going Concern and
Current Working Capital
The Company’s audited financial statements for
fiscal 2023, included in is Annual Report on Form 10-K filed with
the SEC today, contained a going concern opinion from its
independent registered public accounting firm.
Subsequent to its year-end, the Company raised
net proceeds of approximately $2,094,000, after deducing offering
expenses and commissions. The Company believes its working capital
is sufficient to fund operations through July 2023.
Conference Call and Webcast
A live webcast of the conference call and
related earnings release materials can be accessed on the Company’s
Investor Relations website at:
https://audience.mysequire.com/webinar-view?webinar_id=19521825-9284-4391-bfe3-8ed5b4ec0774
A replay of the webcast will be available
through the same link following the conference call. Participants
can also access the call using the dial-in details below:
Date: Thursday, June 29, 2023Time: 4:00 p.m. CT (5:00 pm
ET)Dial-in number: 1-346-248-7799Conference ID:
92979093556Passcode: 980888
About PetVivo
Holdings, Inc.
PetVivo Holdings, Inc. (the “Company”) is an
emerging biomedical device company currently focused on the
manufacturing, commercialization, and licensing of innovative
medical devices and therapeutics for animals. The Company’s
strategy is to leverage human therapies for the treatment of dogs
and horses in a capital and time-efficient way. A key component of
this strategy is the accelerated timeline to revenues for
veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
The Company has a pipeline of additional
products for the treatment of animals and people. A portfolio of
nineteen patents protects the Company’s biomaterials, products,
production processes, and methods of use. The Company’s lead
product is Spryng™, a veterinarian-administered, intraarticular
injection for the treatment of osteoarthritis in dogs and
horses.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
all statements that do not relate solely to historical or current
facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2023, and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events, or otherwise.
Disclosure Information
The Company uses and intends to continue to use
its Investor Relations website as a means of disclosing material
nonpublic information, and for complying with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the Company’s Investor Relations website, in addition to
following the Company’s press releases, SEC filings, public
conference calls, presentations, and webcasts.
Contact:
John Lai, CEOPetVivo Holdings, Inc.Email: info1@petvivo.com(952)
405-6216
PETVIVO HOLDINGS,
INC.CONSOLIDATED STATEMENTS OF
OPERATIONS
|
|
Year Ended March 31, |
|
|
2023 |
|
2022 |
Revenues |
|
$ |
917,162 |
|
|
$ |
115,586 |
|
|
|
|
|
|
|
|
|
|
Cost of
Sales |
|
|
526,817 |
|
|
|
201,154 |
|
Gross Profit (Loss) |
|
|
390,345 |
|
|
|
(85,568 |
) |
|
|
|
|
|
|
|
|
|
Operating
Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and Marketing |
|
|
3,410,277 |
|
|
|
1,347,585 |
|
Research and Development |
|
|
690,577 |
|
|
|
474,881 |
|
General and Administrative |
|
|
5,022,943 |
|
|
|
3,148,494 |
|
|
|
|
|
|
|
|
|
|
Total Operating Expenses |
|
|
9,123,797 |
|
|
|
4,970,960 |
|
|
|
|
|
|
|
|
|
|
Operating Loss |
|
|
(8,733,452 |
) |
|
|
(5,056,528 |
) |
|
|
|
|
|
|
|
|
|
Other
Income |
|
|
|
|
|
|
|
|
Forgiveness of PPP Loan and Accrued Interest |
|
|
- |
|
|
|
31,680 |
|
Interest Income |
|
|
15,844 |
|
|
|
9,853 |
|
Total Other Income |
|
|
15,844 |
|
|
|
41,533 |
|
|
|
|
|
|
|
|
|
|
Net Loss before taxes |
|
|
(8,717,608 |
) |
|
|
(5,014,995 |
) |
|
|
|
|
|
|
|
|
|
Income Tax Provision |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Net Loss |
|
$ |
(8,717,608 |
) |
|
$ |
(5,014,995 |
) |
|
|
|
|
|
|
|
|
|
Net Loss Per Share: |
|
|
|
|
|
|
|
|
Basic and Diluted |
|
$ |
(0.85 |
) |
|
$ |
(0.57 |
) |
|
|
|
|
|
|
|
|
|
Weighted Average Common Shares Outstanding: |
|
|
|
|
|
|
|
|
Basic and Diluted |
|
|
10,222,994 |
|
|
|
8,760,877 |
|
PETVIVO HOLDINGS,
INC.CONSOLIDATED BALANCE SHEETS
|
|
March 31, 2023 |
|
|
March 31, 2022 |
Assets: |
|
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
475,314 |
|
|
$ |
6,106,827 |
|
Accounts receivable |
|
|
86,689 |
|
|
|
2,596 |
|
Inventory, net |
|
|
370,283 |
|
|
|
98,313 |
|
Prepaid expenses and other current assets |
|
|
491,694 |
|
|
|
547,664 |
|
Total Current Assets |
|
|
1,423,980 |
|
|
|
6,755,400 |
|
|
|
|
|
|
|
|
|
|
Property and Equipment,
net |
|
|
630,852 |
|
|
|
311,549 |
|
|
|
|
|
|
|
|
|
|
Other Assets: |
|
|
|
|
|
|
|
|
Operating lease right-of-use |
|
|
317,981 |
|
|
|
299,101 |
|
Patents and trademarks, net |
|
|
38,649 |
|
|
|
48,452 |
|
Security deposit |
|
|
27,490 |
|
|
|
12,830 |
|
Total Other Assets |
|
|
384,120 |
|
|
|
360,383 |
|
Total Assets |
|
$ |
2,438,952 |
|
|
$ |
7,427,332 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders’
Equity: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
588,713 |
|
|
$ |
323,384 |
|
Accrued expenses |
|
|
779,882 |
|
|
|
784,375 |
|
Operating lease liability – short term |
|
|
78,149 |
|
|
|
59,178 |
|
Note payable and accrued interest |
|
|
6,936 |
|
|
|
6,549 |
|
Total Current Liabilities |
|
|
1,453,680 |
|
|
|
1,173,486 |
|
Other Liabilities |
|
|
|
|
|
|
|
|
Note payable and accrued interest (net of current portion) |
|
|
20,415 |
|
|
|
27,201 |
|
Operating lease liability (net of current portion) |
|
|
239,832 |
|
|
|
239,923 |
|
Total Other Liabilities |
|
|
260,247 |
|
|
|
267,124 |
|
Total Liabilities |
|
|
1,713,927 |
|
|
|
1,440,610 |
|
|
|
|
|
|
|
|
|
|
Commitments and
Contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity: |
|
|
|
|
|
|
|
|
Preferred stock, par value $0.001, 20,000,000 shares authorized, no
shares issued and outstanding at March 31, 2023 and March 31,
2022 |
|
|
- |
|
|
|
- |
|
Common stock, par value $0.001, 250,000,000 shares authorized,
10,950,220 and 9,988,361 shares issued and outstanding at March 31,
2023 and March 31, 2022, respectively |
|
|
10,950 |
|
|
|
9,988 |
|
Common Stock to be Issued |
|
|
137,500 |
|
|
|
- |
|
Additional Paid-In Capital |
|
|
72,420,604 |
|
|
|
69,103,155 |
|
Accumulated Deficit |
|
|
(71,844,029 |
) |
|
|
(63,126,421 |
) |
Total Stockholders’ Equity |
|
|
725,025 |
|
|
|
5,986,722 |
|
Total Liabilities and Stockholders’ Equity |
|
$ |
2,438,952 |
|
|
$ |
7,427,332 |
|
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024